It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

How to administer ZARXIO

Should patients need to self-inject, here’s a video on how to administer ZARXIO.

How To Administer ZARXIO

ZARXIO is available with a BD™ UltraSafe Passive® Needle Guard that provides one-handed passive activation.1

zarxio syringe

Not actual size.

ZARXIO strengths

ZARXIO is available in prefilled syringes, in the same 2 dosage strengths as NEUPOGEN® (filgrastim) and has an identical dosing schedule and route of administration to NEUPOGEN®.1,2

Zarxio 300mcg/0.5 ML blue plunger and 480mcg/0.8 mL grey plunger injection syringe dosing information

ZARXIO is administered by subcutaneous injection, short intravenous infusion (15 to 30 minutes)‚ or continuous intravenous infusion.1

You should not inject a dose of ZARXIO less than 0.3 mL (180 mcg) from a ZARXIO prefilled syringe. A dose less than 0.3 mL cannot be accurately measured using the ZARXIO prefilled syringe.1

Learn about ZIEXTENZO (pegfilgrastim-bmez), the long-acting G-CSF treatment option from Sandoz3

G-CSF=granulocyte colony-stimulating factor.

BD is a trademark of Becton, Dickinson and Company.
UltraSafe Passive is a registered trademark of Safety Syringes, Inc.
NEUPOGEN is a registered trademark of Amgen Inc.

References: 1. ZARXIO Prescribing Information. Sandoz Inc. September 2022. 2. NEUPOGEN® Prescribing Information. Amgen Inc. April 2023. 3. ZIEXTENZO Prescribing Information. Sandoz Inc. March 2021.